Treatment outcomes amongst previously antiretroviral-naïve HIV-infected patients starting lopinavir/ritonavir-containing antiretroviral regimens at the Royal Free Hospital

HIV Medicine

Volumn 8, Issue 1, 2007, Pages 55-63

  Smith, Colette J ^a   Phillips, A N ^a   Youle, M S ^b   Sabin, C A ^a   Lampe, F C ^a   Tsintas, R ^b   Tyrer, M ^b   Johnson, M A ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Antiretro viral therapy; CD4 count; Lopinavir ritonavir; Toxicity; Viral load

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA;

ADULT; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT DECISION MAKING; PRIORITY JOURNAL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ADULT; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LONDON; MALE; PYRIMIDINONES; RITONAVIR; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33846329108     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2007.00431.x     Document Type: Article

References (33)

1. Gazzard B, for the BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2005; 6: 1-61.
2. Yeni PG, Hammer SM, Hirsch MS et al. Treatment for adult HIV infection: 2004 Recommendations of the International AIDS Society-USA Panel. J Am Med Assoc 2004; 292: 251-265.
3. Walmsley S, Bernstein B, King M et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Eng J Med 2002; 346: 2039-2046.
4. Manfredi R, Calza L, Chiodo F. First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naïve patients. AIDS 2004; 18: 2331-2333.
5. Smith CJ, Phillips AN, Hill T et al. The rate of viral rebound after attainment of viral load below 50 copies/ml according to specific antiretroviral drugs in use. J Infect Dis 2005; 192: 1387-1397.
6. Romano L, Peduzzi C, Venturi G et al. Treatment with lopinavir/ritonavir in heavily pretreated subjects failing multiple antiretroviral regimens in clinical practice. J Acquir Immune Defic Syndr 2002; 30: 533-535.
7. Smith CJ, Sabin CA, Johnson MA et al. Participation in clinical trials at the Royal Free Hospital: Characteristics of those included and impact on treatment outcomes. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2005 [Abstract 618].
8. US Food and Drug Administration. Guidance For Industry: Antiretroviral Drugs Using Plasma HIV RNA Measurements-Clinical Considerations for Accelerated and Traditional Approval. http://fda.gov/cder/guidance/ index.htm 2006.
9. van Leth F, Phanuphak P, Ruxrungtham K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomised open-label trial, the 2NN Study. Lancet 2004; 363: 1253-1263.
10. Murphy RL, Brun S, Hicks C et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 2001; 15: F1-F9.
11. Pulido F, Arribas J, Miro JM et al. Clinical, virologic, and immunologic response to efavirenz- or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 Study). J Acquir Immune Defic Syndr 2004; 35: 343-350.
12. Cozzi-Lepri A, Phillips AN, d'Arminio Monforte A et al. Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I. Co. N.A.) study. J Infect Dis 2002; 185: 1062-1069.
13. Sabin CA, Lampe F, Chaloner C et al. An audit of antiretroviral treatment use in HIV-infected patients in a London clinic. HIV Med 2003; 4: 87-93.
14. University of Zurich. http://research-projects.unizh.ch/med/unit41700/ area524/p5798.htm 2005.
15. Garcia-Diaz A, Clewley GS, Booth CL, Labett W, McAllister N, Geretti AM. Comparative evaluation of the performance of the Abbott real-time human immunodeficiency virus type 1 (HIV-1) assay for measurement of HIV-1 plasma viral load following automated specimen preparation. J Clin Microbiol 2006; 44: 1788-1791.
16. Smith CJ, Sabin CA, Lampe FC et al. The relationship between CD4 cell nadirs and the toxicity profiles of antiretroviral regimens. Antiviral Ther 2005; 10: 459-467.
17. O'Brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003; 34: 407-414.
18. Youle M, Sawyer W, for the HIV Health Economics Collaboration Reasons for discontinuation of antiretroviral treatment: A clinical survey. AIDS 1998; 12: P186.
19. Van Roon EN, Verzijl JM, Juttmann JR. Incidence of discontinuation of highly active antiretroviral therapy (HAART) and its determinants. J Acquir Immune Defic Syndr 1999; 20: 290-294.
20. Dorrucci M, Pezzotti P, Grisorio B et al. Time to discontinuation of the first highly active antiretroviral therapy regimen: A comparison between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimens. AIDS 2001; 15: 1733-1736.
21. Smith CJ, Sabin CA, Youle MS et al. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis 2004; 190: 1860-1868.
22. Kaufmann GR, Bloch M, Zaunders JJ, Smith D, Cooper DA. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy. AIDS 2000; 14: 959-969.
23. Connick E, Lederman MM, Kotzin BL et al. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis 2000; 181: 358-363.
24. Olsen CH, Gatell J, Ledergerber B et al. Risk of AIDS and death at given HIV-RNA and CD4 cell counts, in relation to specific antiretroviral drugs in the regimen. AIDS 2005; 19: 319-330.
25. CASCADE Collaboration. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 2003; 362: 1267-1274.
26. Phillips AN, Ledergerber B, Horban A et al. Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. AIDS 2004; 18: 1795-1804.
27. Grabar S, Pradier C, Le Corfec E et al. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS 2000; 14: 141-149.
28. Phillips AN, Staszewski S, Weber R et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. J Am Med Assoc 2001; 286: 2560-2567.
29. Descamps D, Flandre P, Calvez V et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. J Am Med Assoc 2000; 283: 205-211.
30. Miller V, Staszewski S, Sabin CA et al. CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load. J Infect Dis 1999; 180: 530-533.
31. Mocroft A, Ruiz L, Reiss P et al. Virological rebound after suppression on highly active antiretroviral therapy. AIDS 2003; 17: 1741-1751.
32. Frater AJ, Dunn DT, Beardall AJ et al. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS 2002; 16: 1139-1146.
33. Le Moing V, Chene G, Carrieri MP et al. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 2002; 16: 21-29.